NewsWatch: Here’s what legendary investor Bill Miller said in his final investment letter

Biogen’s New Alzheimer’s Drug Meets Slow Rollout

The drugmaker’s revenue from the drug, Aduhelm, was $300,000 in the first full quarter since its approval, a figure well below analyst expectations. Sales could be minimal through the end of the year, the company said.

This post was originally published on Market Watch

Financial News

Daily News on Investing, Personal Finance, Markets, and more!